Dexcom announced that the FDA has approved its Dexcom G4 Platinum continuous glucose monitor (CGM) for patients with diabetes.
Clinical studies report up to approximately 19% improvement in overall accuracy compared to the Seven Plus, and approximately a 30% improvement in accuracy in the hypoglycemia range (eg, when blood glucose <70mg/dL). Unlike the traditional “finger-stick” blood glucose monitor, CGM provides an in-motion picture that shows not only glucose levels, but also the speed and direction in which it is moving, and alerts the user to sudden changes so they can take action.
Some features of the Dexcom G4 Platinum CGM include:
- Longest transmission range, enabling patient flexibility and convenience
- A smaller, discrete profile
- A color LCD display for easy viewing
- Customizable alerts with specific tones
- “Hypo alert” setting at 55mg/dL that provides an increased level of safety
The tiny sensor is inserted by the user under the skin on the abdomen. A small transmitter sends data wirelessly to a sleek and small monitor, which easily fits in a purse or pocket. It provides data every 5 minutes for up to 7 consecutive days, quickly and easily showing the body’s response to medication, food and exercise. If users are outside their target zones, configurable alarms alert them so that they can take action.
Dexcom G4 Platinum CGM is expected to ship in the next couple of weeks.
For more information call (888) 738-3646 or visit www.dexcom.com.